LXREPAIR is a biotech company developing in vitro diagnostic (IVD) assays to predict cancer therapy outcomes. Its innovative assays are based on functional signatures of DNA repair capacity that can be detected on a biochip, from a simple blood sample. Our first IVD assay, Safer RAD-LX for which a very promising clinical proof of concept has been obtained in breast and prostate settings, will predict severe late side effects. It will be launched on the market in 2024. This assay will enable the oncologist to personalize the cancer patient’s treatment and to predict toxicity. After toxicity induced by radiation therapy,toxicity relating to DNA damaging chemotherapies such as Oxaliplatin or 5FU will also be tackled and a product will be developed in H&N cancer for prediction of chemotoxicity.